Purpose of Review Immune checkpoint inhibitors, such as monoclonal antibodies targeting
CTLA-4, PD-1, and PD-L1, have improved the outcome of many malignancies, but serious …

Although there have been many improvements in prognosis for patients with cancer, anticancer
therapies are burdened by the risk of cardiovascular toxicity. Heart failure is one of the …

Systemic sclerosis is an auto-immune disease characterized by skin involvement that often
affects multiple organ systems. Pulmonary hypertension is a common finding that can …

Purpose of Review Along with population aging, the incidence of both heart failure (HF) and
cancer is increasing. However, little is known about new-onset cancer in HF patients. This …

Metabolic syndrome (MetS) is a well established risk factor for cardiovascular (CV) diseases.
In addition, several studies indicate that MetS correlates with the increased risk of cancer in …

Background the European Society of Cardiology Heart Failure Association (HFA) together
with the International Cardio-Oncology Society (ICOS) proposed charts for baseline CV risk …

Anthracyclines are widely used in anticancer protocols, but can induce cardiotoxicity by
mechanisms that mainly involve oxidative damage and mitochondrial dysfunction. Radiotherapy (…

Rationale Pulmonary arterial hypertension (PAH) is a rare disease characterised by limited
survival despite remarkable improvements in therapy. The causes, clinical burden and …

Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition
is still characterized by an extremely poor prognosis. In this review, we discuss the use of …

Aims As the world population grows older, the co‐existence of cancer and cardiovascular
comorbidities becomes more common, complicating management of these patients. Here, we …